RNA-based therapeutics: from antisense oligonucleotides to miRNAs
S Bajan, G Hutvagner - Cells, 2020 - mdpi.com
The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was
United States Food and Drug Administration (FDA) approved. This promises to be a rapidly
expanding market, as many emerging biopharmaceutical companies are developing RNA
interference (RNAi)-based, and RNA-based antisense oligonucleotide therapies. However,
miRNA therapeutics are noticeably absent. miRNAs are regulatory RNAs that regulate gene …
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was
United States Food and Drug Administration (FDA) approved. This promises to be a rapidly
expanding market, as many emerging biopharmaceutical companies are developing RNA
interference (RNAi)-based, and RNA-based antisense oligonucleotide therapies. However,
miRNA therapeutics are noticeably absent. miRNAs are regulatory RNAs that regulate gene …
以上显示的是最相近的搜索结果。 查看全部搜索结果